CELU
Celularity Inc - Ordinary Shares - Class A

2,416
Loading...
Loading...
News
all
press releases
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L
Nationally Established Q Code Will Further Support the Use of Biovance 3L by Physicians to Treat Wound Care Patients in Office SettingsFLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE...
Globe Newswire·1y ago
News Placeholder
More News
News Placeholder
Kuehn Law Encourages Investors of Celularity Inc. to Contact Law Firm
NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Celularity, Inc. (NASDAQ: CELU) breached...
Globe Newswire·1y ago
News Placeholder
Celularity submits request to FDA for orphan drug designation for PDA-002
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy
Company Has Already Received IND Clearance from the FDA and Plans to Begin Phase 1/2 Study in 2024 with Off-the-Shelf, Placental-Derived Cell TherapyFLORHAM PARK, N.J., March 20, 2024 (GLOBE...
Globe Newswire·1y ago
News Placeholder
Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit
Presentation Will Discuss Cellular Immunotherapy's Potential Role in Treating Chronic Conditions and Extending People's LivesFLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc...
Globe Newswire·1y ago
News Placeholder
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
Keynote Will Discuss Cellular Immunotherapy's Potential for Treating Chronic Conditions, Including Cancer, Multiple Sclerosis and Parkinson's DiseaseFLORHAM PARK, N.J., March 12, 2024 (GLOBE...
Globe Newswire·1y ago
News Placeholder
Celularity to present in vivo data from T-cell therapy platform at AACR
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
Company presenting an in vivo study of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells at AACR Annual Meeting 2024FLORHAM PARK, N.J...
Globe Newswire·2y ago
News Placeholder
Celularity trading halted, news pending
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Celularity Stock to Reverse Split on Thursday, February 29th (NASDAQ:CELU)
Celularity Inc. (NASDAQ:CELU Free Report)s stock is going to reverse split before the market opens on Thursday, February 29th. The 1-10 reverse split was announced on Thursday...
Zolmax·2y ago

Latest CELU News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.